Details for Patent: 8,629,162
✉ Email this page to a colleague
Which drugs does patent 8,629,162 protect, and when does it expire?
Patent 8,629,162 protects KALYDECO, TRIKAFTA (COPACKAGED), and SYMDEKO (COPACKAGED), and is included in five NDAs.
This patent has one hundred and seventeen patent family members in twenty-six countries.
Summary for Patent: 8,629,162
Title: | Modulators of ATP-binding cassette transporters |
Abstract: | The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. |
Inventor(s): | Hadida-Ruah; Sara (La Jolla, CA), Hazlewood; Anna (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Van Goor; Fredrick (San Diego, CA), Singh; Ashvani (San Diego, CA), Zhou; Jinglan (San Diego, CA), McCartney; Jason (Cardiff by the Sea, CA) |
Assignee: | Vertex Pharmaceuticals Incorporated (Cambridge, MA) |
Application Number: | 13/647,034 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,629,162
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-004 | May 3, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO | ⤷ Try a Trial | ||||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-005 | May 3, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO | ⤷ Try a Trial | ||||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA | ⤷ Try a Trial | ||||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO | ⤷ Try a Trial | ||||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-001 | Mar 17, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,629,162
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2005258320 | ⤷ Try a Trial | |||
Australia | 2010249302 | ⤷ Try a Trial | |||
Australia | 2010251787 | ⤷ Try a Trial | |||
Australia | 2010251789 | ⤷ Try a Trial | |||
Australia | 2010327993 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |